An open, randomized, controlled, phase II, single centre, two-period cross-over study to compare the quality of life and toxicity experienced on PEG interferon with interferon-α2b in patients with multiple myeloma maintained on a steady dose of interferon-α2b

Purpose: To compare the effects of pegylated interferon-alpha 2b (P-IFN) and interferon-alpha 2b (IFN) on quality of life (QoQ and toxicity in patients with multiple myeloma maintained on a steady dose of IFN. Patients and methods: Consenting, eligible myeloma patients on IFN maintenance therapy for at least 6 weeks were randomly (1:1) allocated to receive P-IFN for 3 months followed by IFN for 3 months, or to continue with IFN for 3 months followed by P-IFN for 3 months (cross-over design). Patients were assessed for toxicity and QoL. Dose of P-IFN was equivalent to IFN. Results: The study enrolled 60 patients. At enrolment, 35 patients were in complete remission, 20 in partial remission and 5 were minimal responders. P-IFN was associated with significantly better global QoL score (mean difference 8.4; P 0.0002). There was a significant improvement in functional scales-physical (P = 0.03), emotional (P = 0.04), social (P 0.0008) with P-IFN. Fatigue (P = 0.0003), pain (P = 0.02) and appetite loss (P = 0.003) symptom scales were less in patients while on P-lFN. There were no statistically significant differences between treatment arms in QoL as measured by QLQ-MY24. Conclusion: These data suggest that patients on P-IFN have a better QoL. Dose escalation studies are warranted to investigate potential impact on survival.